Relative release of interleukin-1 beta and interleukin-1 receptor antagonist by alveolar macrophages. A study in asbestos-induced lung disease, sarcoidosis, and idiopathic pulmonary fibrosis.
We examined the influence of untreated interstitial lung disease (ILD) on the in vitro release of interleukin-1 beta (IL-1 beta) and interleukin-1 receptor antagonist (IL-Ira) from alveolar macrophages (AM); AM were harvested from normal volunteers, ILD patients, and patients with asbestos-related pleural disease but no ILD. AM were cultured for 24 h and assays for IL-1 beta and IL-1ra were done using sensitive and specific enzyme-linked immunosorbent assay. A greater amount of IL-1 beta was detected in AM supernatants from asbestosis, sarcoidosis, and IPF patients than in those from normal subjects. The IL-1 beta:IL-1ra ratio (IL-1 beta activity index [IL-1AI]) was significantly lower in supernatants of normal macrophages compared with macrophage supernatants from individuals with ILD. The IL-1AI correlated with bronchoalveolar lavage cellularity, a marker of disease activity. Current smoking was associated with lower IL-1 beta and IL-1ra release in ILD. The IL-1AI is a convenient method for comparison of IL-1 beta activity between patient populations.
Kline
J N
JN
Department of Internal Medicine, Veteran's Affairs Medical Center, Iowa City.
Schwartz
D A
DA
Monick
M M
MM
Floerchinger
C S
CS
Hunninghake
G W
GW
D000328:Adult; D000368:Aged; D001195:Asbestosis / Q000378:metabolism / Q000473:pathology*; D001992:Bronchoalveolar Lavage Fluid / Q000473:pathology; D002478:Cells, Cultured; D005260:Female; D005355:Fibrosis; D006801:Humans; D007375:Interleukin-1 / Q000032:analysis / Q000378:metabolism*; D007962:Leukocytes / Q000378:metabolism / Q000473:pathology; D008171:Lung Diseases / Q000378:metabolism / Q000473:pathology*; D016676:Macrophages, Alveolar / Q000378:metabolism*; D008297:Male; D008875:Middle Aged; D010995:Pleural Diseases / Q000378:metabolism / Q000473:pathology; D011658:Pulmonary Fibrosis / Q000378:metabolism / Q000473:pathology*; D017472:Receptors, Interleukin-1 / Q000032:analysis / Q000037:antagonists & inhibitors*; D012507:Sarcoidosis / Q000378:metabolism / Q000473:pathology*; D012907:Smoking / Q000378:metabolism / Q000473:pathology
D007375:Interleukin-1; D017472:Receptors, Interleukin-1